Xcout Intel
Imvax, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Imvax, Inc. among biotechnology companies — ranked by similarity to what Imvax, Inc. actually does, not by market-cap band.
Subscribe to see Imvax, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Imvax, Inc.
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Imvax, Inc. at a glance
Imvax, Inc. is a biotechnology company headquartered in United States. It has raised at least $181.1M across the 4 funding rounds on record. Its most recent funding round, Series C, raised $29M in January 2025. Xcout tracks 9 named people at Imvax, Inc., including Sean P. Hemingway (Chief Operating Officer).
Imvax, Inc. leadership
- Sean P. HemingwayChief Operating Officer
- John M. LimongelliChief Financial Officer and Chief Legal Officer
- John P. FureyExecutive Chairman of the Board
- Peter B. CorrImvax Co-Founder; Auven Therapeutics Management LLP
- Ira BrindPresident, Brind Investments, Inc.
- David G. BunningTLP Investment Partners LLC
3 more named people on record for Imvax, Inc., with roles, board committees and tenure — see the full roster →
Imvax, Inc. funding rounds
At least $181.1M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $29M | 4 named | |
| — | $112.4M | 5 named | |
| SEC Form D filing | $24.8M | — | |
| Series A | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Imvax, Inc. competitors
Ranked by semantic similarity — how close each company is to Imvax, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Similar biotechnology company
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Similar biotechnology company
IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. Its proprietary T-win® technology is designed to modulate the tumor microenvironment by targeting both tumor cells and immune-suppressive cells, aiming to improve treatment outcomes for patients with melanoma and other tumor types.
Similar biotechnology company
CancerVAX, Inc. is an American biotechnology and pharmaceutical company based in Lehi, Utah, founded in 2021. The company focuses on developing a breakthrough universal cancer treatment platform designed to disguise cancer cells.
Similar biotechnology company
Carisma Therapeutics is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on discovering and developing engineered macrophage-based immunotherapies.
Similar biotechnology company
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Similar biotechnology company
GlobeImmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Louisville, Colorado, focused on developing therapeutic vaccines to treat cancer and infectious diseases.
Biotech
ImmPACT Bio USA, Inc. is a clinical-stage biotechnology company headquartered in West Hills, California. The company focuses on developing advanced cell therapies and immunotherapies to treat cancer and other serious diseases.
Biotech
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Similar biotechnology company
Immune Design Corp. is a clinical-stage immunotherapy company with offices in Seattle, Washington, and South San Francisco, California, specializing in novel drug discovery and treatment technologies.
Similar biotechnology company
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Imvax, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Imvax, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →